Charles River Laboratories International (NYSE:CRL) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Charles River Laboratories International (NYSE:CRL) issued its quarterly earnings results on Wednesday. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16, Zacks reports. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.46 earnings per share. Charles River Laboratories International updated its FY 2025 guidance to 9.100-9.600 EPS and its FY25 guidance to $9.10-$9.60 EPS.

Charles River Laboratories International Price Performance

CRL opened at $162.63 on Friday. The stock has a market cap of $8.32 billion, a P/E ratio of 1,084.19, a P/E/G ratio of 6.77 and a beta of 1.37. Charles River Laboratories International has a 12 month low of $150.79 and a 12 month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $173.39 and a 200 day simple moving average of $188.81.

Wall Street Analyst Weigh In

CRL has been the topic of a number of recent research reports. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research note on Monday, November 18th. Evercore ISI upped their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Morgan Stanley reduced their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. Finally, Barclays cut their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $195.71.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).